title: Endothelin A receptor antagonism enhances inhibitory effects of anti-ganglioside GD2 monoclonal antibody on invasiveness and viability of human osteosarcoma cells.
abstract: Endothelin-1 (ET-1)/endothelin A receptor (ETAR) signaling is important for osteosarcoma (OS) progression. Monoclonal antibodies (mAbs) targeting ganglioside GD2 reportedly inhibit tumor cell viability independent of the immune system. A recent study suggests that ganglioside GD2 may play an important role in OS progression. In the present study, we for the first time explored the effects of anti-GD2 mAb alone or in combination with ETAR antagonist on OS cell invasiveness and viability. Human OS cell lines Saos-2, MG-63 and SJSA-1 were treated with control IgG (PK136 mAb, 50 µg/mL), anti-GD2 14G2a mAb (50 µg/mL), selective ETAR antagonist BQ123 (5 µM), or 14G2a (50 µg/mL)+BQ123 (5 µM). Cells with knockdown of ETAR (ETAR-shRNA) with or without 14G2a mAb treatment were also tested. Cells treated with selective phosphatidylinositide 3-kinase (PI3K) inhibitor BKM120 (50 µM) were used as a positive control. Our results showed that BQ123, ETAR-shRNA and 14G2a mAb individually decreased cell invasion and viability, matrix metalloproteinase-2 (MMP-2) expression and activity, PI3k activity, and phosphorylation at serine 473 (ser473) of Akt in OS cells. 14G2a mAb in combination with BQ123 or ETAR-shRNA showed significantly stronger inhibitory effects compared with each individual treatment. In all three cell lines tested, 14G2a mAb in combination with BQ123 showed the strongest inhibitory effects. In conclusion, we provide the first in vitro evidence that anti-ganglioside GD2 14G2a mAb effectively inhibits cell invasiveness, MMP-2 expression and activity, and cell viability in human OS cells. ETAR antagonist BQ123 significantly enhances the inhibitory effects of 14G2a mAb, likely mainly through inhibiting the PI3K/Akt pathway. This study adds novel insights into OS treatment, which will serve as a solid basis for future in vivo studies on the effects of combined treatment of OS with anti-ganglioside GD2 mAbs and ETAR antagonists.
authors.affiliation: Department of Orthopaedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
authors.forename: Bo
authors.initials: B
authors.lastname: Liu
authors.affiliation: Hunan Provincial Health Bureau, Changsha, Hunan, P. R. China.
authors.forename: Yi
authors.initials: Y
authors.lastname: Wu
authors.affiliation: Department of Orthopaedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
authors.forename: Yu
authors.initials: Y
authors.lastname: Zhou
authors.affiliation: Department of Orthopaedics, The Second Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China.
authors.forename: Dan
authors.initials: D
authors.lastname: Peng
mesh_terms: D000631:Aminopyridines / Q000494:pharmacology; D000911:Antibodies, Monoclonal / Q000276:immunology / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000187:drug effects; D065130:Endothelin A Receptor Antagonists / Q000494:pharmacology*; D005732:Gangliosides / Q000037:antagonists & inhibitors / Q000276:immunology*; D006801:Humans; D009025:Morpholines / Q000494:pharmacology; D009361:Neoplasm Invasiveness / Q000517:prevention & control; D012516:Osteosarcoma / Q000378:metabolism*; D019869:Phosphatidylinositol 3-Kinases / Q000378:metabolism; D000081082:Phosphoinositide-3 Kinase Inhibitors
chemical_list: D000631:Aminopyridines; D000911:Antibodies, Monoclonal; D065130:Endothelin A Receptor Antagonists; D005732:Gangliosides; D009025:Morpholines; D019869:Phosphatidylinositol 3-Kinases; D000081082:Phosphoinositide-3 Kinase Inhibitors; C571178:NVP-BKM120; C019403:ganglioside, GD2
references.citation: J Transl Med. 2012 Nov 07;10:219
references.pmid: 23134699
references.citation: Biochem Biophys Res Commun. 2013 Oct 18;440(2):229-34
references.pmid: 24041695
references.citation: Cancer. 2014 Feb 15;120(4):548-54
references.pmid: 24166473
references.citation: Cancer Lett. 2013 Dec 1;341(2):248-64
references.pmid: 23962557
references.citation: J Immunol. 2008 Aug 1;181(3):1969-77
references.pmid: 18641334
references.citation: Int J Oncol. 2012 Nov;41(5):1809-19
references.pmid: 22948234
references.citation: PLoS One. 2013;8(1):e53906
references.pmid: 23372675
references.citation: Biochim Biophys Acta. 2008 Mar;1780(3):421-33
references.pmid: 17991443
references.citation: Mol Pharmacol. 2006 Feb;69(2):520-31
references.pmid: 16291872
references.citation: J Hepatol. 2009 Mar;50(3):528-37
references.pmid: 19155088
references.citation: Nat Rev Cancer. 2003 Feb;3(2):110-6
references.pmid: 12563310
references.citation: Eur J Cancer. 2011 Oct;47(15):2353-63
references.pmid: 21680174
references.citation: Clin Sci (Lond). 2006 Jun;110(6):645-54
references.pmid: 16417466
references.citation: J Mol Med (Berl). 2012 Jun;90(6):695-706
references.pmid: 22207485
references.citation: PLoS One. 2011;6(5):e20348
references.pmid: 21637818
references.citation: Clin Orthop Relat Res. 2011 Nov;469(11):3190-9
references.pmid: 21656314
references.citation: Cancer Lett. 2013 Jun 10;333(2):194-204
references.pmid: 23370223
references.citation: Biochem Biophys Res Commun. 2011 Jan 28;404(4):1039-43
references.pmid: 21187062
references.citation: Glycobiology. 2012 Jun;22(6):806-16
references.pmid: 22301273
references.citation: Curr Cancer Drug Targets. 2010 Mar;10(2):200-9
references.pmid: 20201786
references.citation: Mol Med Rep. 2013 Feb;7(2):608-12
references.pmid: 23229760
references.citation: Circulation. 2010 Jun 15;121(23):2565-74
references.pmid: 20516375
references.citation: Clin Cancer Res. 2003 Nov 15;9(15):5442-53
references.pmid: 14654523
references.citation: Mol Med Rep. 2012 Jun;5(6):1391-5
references.pmid: 22446894
references.citation: Am Fam Physician. 2002 Mar 15;65(6):1123-32
references.pmid: 11925089
references.citation: Food Chem. 2014 Jan 1;142:66-71
references.pmid: 24001813
references.citation: Life Sci. 2013 Nov 4;93(18-19):655-63
references.pmid: 24044886
references.citation: Cancer Treat Res. 2009;152:3-13
references.pmid: 20213383
references.citation: J Pediatr Hematol Oncol. 2014 Mar;36(2):152-5
references.pmid: 24065045